Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.5694/mja2.50698 http://scihub22266oqcxt.onion/10.5694/mja2.50698 32677734!7404664!32677734     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\32677734.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Med+J+Aust 2020 ; 213 (3): 134-139 Nephropedia Template TP {{tp|p=32677734|t=2020. Clinical presentation and management of COVID-19 |pdf=|usr=}}{{32677734}} gab.com Text Clinical presentation and management of COVID-19 JO: Med J Aust http://www.kidney.de/pget.php?&tw=1&pmid=32677734 #FOAvip The rapid spread of severe acute respiratory syndrome coronavirus 2 led to the declaration of a global pandemic within 3 months of its emergence. The majority of patients presenting with coronavirus disease 2019 (COVID-19) experience a mild illness that can usually be managed in the community. Patients require careful monitoring and early referral to hospital if any signs of clinical deterioration occur. Increased age and the presence of comorbidities are associated with more severe disease and poorer outcomes. Treatment for COVID-19 is currently predominantly supportive care, focused on appropriate management of respiratory dysfunction. Clinical evidence is emerging for some specific therapies (including antiviral and immune-modulating agents). Investigational therapies for COVID-19 should be used in the context of approved randomised controlled trials. Australian clinicians need to be able to recognise, diagnose, manage and appropriately refer patients affected by COVID-19, with thousands of cases likely to present over the coming years. Twit Text FOAVip Clinical presentation and management of COVID-19 ????Med J Aust http://www.kidney.de/pget.php?&tw=1&pmid=32677734 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32677734 #FOAvip English Wikipedia <ref>{{Cite pmid|32677734}}</ref> Clinical presentation and management of COVID-19 #MMPMID32677734 Thevarajan I; Buising KL; Cowie BC Med J Aust 2020[Aug]; 213 (3): 134-139 PMID32677734show ga The rapid spread of severe acute respiratory syndrome coronavirus 2 led to the declaration of a global pandemic within 3 months of its emergence. The majority of patients presenting with coronavirus disease 2019 (COVID-19) experience a mild illness that can usually be managed in the community. Patients require careful monitoring and early referral to hospital if any signs of clinical deterioration occur. Increased age and the presence of comorbidities are associated with more severe disease and poorer outcomes. Treatment for COVID-19 is currently predominantly supportive care, focused on appropriate management of respiratory dysfunction. Clinical evidence is emerging for some specific therapies (including antiviral and immune-modulating agents). Investigational therapies for COVID-19 should be used in the context of approved randomised controlled trials. Australian clinicians need to be able to recognise, diagnose, manage and appropriately refer patients affected by COVID-19, with thousands of cases likely to present over the coming years. |Age Factors[MESH] |Antiviral Agents/therapeutic use[MESH] |Australia/epidemiology[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Coronavirus Infections/*diagnosis/epidemiology/*therapy[MESH] |Humans[MESH] |Immunologic Factors/therapeutic use[MESH] |Oxygen Inhalation Therapy[MESH] |Pandemics[MESH] |Pneumonia, Viral/*diagnosis/epidemiology/*therapy[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH]Clinical presentation and management of COVID-19 (epmc).pdf DeepDyve Pubget Overpricing